GCM
TIL icon

Graham Capital Management’s Instil Bio TIL Stock Holding History

Graham Capital Management’s Portfolio TIL Stock Details TIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,995
Closed -$193K – 1342
2022
Q3 		$193K Sell
1,995
-1,466
-42% -$168K 0.01% 993
2022
Q2 		$319K Buy
+3,461
New +$490K 0.01% 809

Other funds holding TIL

CVV
Curative Ventures V Dallas, Texas $15.6M AUM 52.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Graham Capital Management's TIL Position: Q4 2022 in Review

Graham Capital Management sold out of Instil Bio (TIL) in Q4 2022, closing a stake of 1,995 shares — an estimated $193K sold.

Graham Capital Management first reported a position in TIL in Q2 2022 and held it in 2 quarters. The position peaked at $319K in Q2 2022. 78 funds tracked by Wall St. Rank hold TIL as of Q4 2022.

  • Graham Capital Management reported no remaining Instil Bio position as of Q4 2022 after selling out during the quarter.
  • Graham Capital Management sold 1,995 Instil Bio shares in Q4 2022, an estimated $193K.
  • Graham Capital Management first reported a position in Instil Bio in Q2 2022 and held it in 2 quarters.
  • Graham Capital Management's Instil Bio position peaked at $319K in Q2 2022.
  • 78 funds tracked by Wall St. Rank held Instil Bio as of Q4 2022.

Based on Graham Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.